Prospective clinical study of continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-15007024

Enrollment

Unknown

Registered

2015-06-11

Start date

2014-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

treatment group:continuous low-dose cyclophosphamide and prednisone

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with MM who fulfilled the following criteria were enrolled: 1. diagnosis of R/R MM established using the International Myeloma Working Group (IMWG) criteria; 2. age>18 years; 3. New York Heart Association (NYHA)>class III; 4. left ventricular ejection fraction (LVEF) less than 50% and serum B-type natriuretic peptide (BNP) more than 459 pg/L.

Exclusion criteria

Exclusion criteria: Patients with the following medical conditions were excluded: 1. the presence of uncontrolled pulmonary or systemic infection, such as active tuberculosis, pulmonary aspergillosis, human immunodef ciency virus (HIV) infection, active hepatitis infection; 2. diabetic ketoacidosis or hyperglycemic hyperosmolar status; 3. past history of allergy to CTX or prednisone; 4. psychiatric disorder; 5. pregnant or lactating women and women with child-bearing ability who were not willing to take contraceptive measures.

Design outcomes

Primary

Measure	Time frame
OS;PFS;	—

Countries

China

Contacts

Public ContactZhou Fan

zfsh257@163.com+86 13585710073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026